Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
More effective treatments to reduce pathological alcohol drinking are needed. The glutamatergic system and the NMDA receptor (NMDAR), in particular, are implicated in behavioral and molecular consequences of chronic alcohol use, making the NMDAR a promising target for novel pharmacotherapeutics. Eth...
Main Authors: | Summer L. Thompson, Carol A. Gianessi, Stephanie S. O'Malley, Dana A. Cavallo, Julia M. Shi, Jeanette M. Tetrault, Kelly S. DeMartini, Ralitza Gueorguieva, Brian Pittman, John H. Krystal, Jane R. Taylor, Suchitra Krishnan-Sarin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.709559/full |
Similar Items
-
Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice
by: Xin-Ming Luo, et al.
Published: (2021-01-01) -
«Caractérisation de sept lignées cellulaires humaines de cancer de vessie pour les principaux marqueurs de la transition épithélio-mésenchymateuse, Twist1 et E-cadhérine, et pour une nouvelle drogue, le saracatinib. »
by: Lortal Canguilhem, Barbara
Published: (2012) -
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
by: Liwei Lang, et al.
Published: (2018-06-01) -
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
by: Xia Liao, et al.
Published: (2020-01-01) -
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro
by: Jin Soo Shin, et al.
Published: (2018-05-01)